Table 4. A summary of the incidence of TEAEs in the safety population.^* .

TEAEs	Treatment group
	D3P (n = 111)		M3P (n = 109)
	All grades (n%)	Grade 3–5 (n%)	All grades (n%)	Grade 3–5 (n%)
Neutropenia	65 (58.56)	64 (57.66)	58 (53.21)	50 (45.87)
Leukopenia	22 (19.82)	19 (17.12)	33 (30.28)	25 (22.94)
Alopecia	9 (8.11)	4 (3.6)	3 (2.75)	1 (0.92)
Infection	6 (5.41)	5 (4.5)	6 (5.5)	5 (4.59)
Fever	6 (5.41)	4 (3.6)	1 (0.92)	1 (0.92)
Anemia	5 (4.5)	4 (3.6)	4 (3.67)	3 (2.75)
Nausea	5 (4.5)	0 (0.00)	4 (3.67)	1 (0.92)
Fatigue	4 (3.6)	0 (0.00)	10 (9.17)	4 (3.67)
Diarrhea	4 (3.6)	2 (1.8)	0 (0.0)	0 (0.0)
Febrile neutropenia	2 (1.8)	2 (1.8)	0 (0.0)	0 (0.0)
Pharyngitis	2 (1.8)	1 (0.9)	2 (1.83)	0 (0.0)
Oral ulcer	2 (1.8)	1 (0.9)	2 (1.83)	0 (0.0)
Hypokalemia	2 (1.8)	2 (1.8)	1 (0.92)	1 (0.92)
Cardiac failure	1 (0.9)	1 (0.9)	0 (0.0)	0 (0.0)
Peripheral edema	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
Erythra	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
Vomiting	1 (0.9)	0 (0.0)	3 (2.75)	1 (0.92)
Bone pain	1 (0.9)	0 (0.0)	3 (2.75)	2 (1.83)
Hyponatremia	1 (0.9)	1 (0.9)	2 (1.83)	2 (1.83)
Allergic reactions	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)

Abbreviations: TEAEs = treatment-emergent-adverse-events；NCI-CTC = National Cancer Institute-Common Toxicity Criteria.

* The sequence of TEAEs was in the order of decreasing frequency, ordered by D3P arm.